|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12345678910111213...156157» |
- | Trial completion, Trial completion date, Trial primary completion date, Compliance, Adherence: ESSTIM: Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus (clinicaltrials.gov) - Oct 17, 2018
P=N/A, N=158, Completed, Sponsor: University Hospital, Lille
Recruiting --> Completed | Trial completion date: Dec 2017 --> Dec 2016 | Trial primary completion date: Dec 2017 --> Nov 2016
- | autologous mesenchymal stem cells / Tianjin Medical University General Hospital
Trial completion, Phase classification: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders (clinicaltrials.gov) - Oct 17, 2018
P2a, N=15, Completed, Sponsor: Tianjin Medical University General Hospital
Recruiting --> Completed | Trial completion date: Dec 2017 --> Dec 2016 | Trial primary completion date: Dec 2017 --> Nov 2016 Recruiting --> Completed | Phase classification: P2 --> P2a
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Monotherapy: A Longitudinal Study of ACTEMRA (clinicaltrials.gov) - Oct 17, 2018
P1/2, N=10, Completed, Sponsor: Fu-Dong Shi
Recruiting --> Completed | Phase classification: P2 --> P2a Active, not recruiting --> Completed
- | Lemtrada (alemtuzumab) / Sanofi
Trial completion, MRI, Metastases: iCAMMS-IST: Advanced MRI Measures of Repair in Alemtuzumab Treated Patients (clinicaltrials.gov) - Oct 17, 2018
P3, N=27, Completed, Sponsor: University of British Columbia
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Trial completion date: Walk SLE: Walk With Ease Program For Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 16, 2018
P=N/A, N=76, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Aug 2018
- | tilarginine (L-NMMA) / Arginox Pharma, Houston Methodist Research Institute
Trial completion, Trial completion date: Diameter Changes of Retinal Vessels During Hypoxia (clinicaltrials.gov) - Oct 16, 2018
P=N/A, N=58, Completed, Sponsor: University of Aarhus
Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Aug 2018 Recruiting --> Completed | Trial completion date: Jun 2016 --> Mar 2016
- | metformin / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: adAPT: Autoimmune Diabetes Accelerator Prevention Trial (clinicaltrials.gov) - Oct 16, 2018
P4, N=0, Withdrawn, Sponsor: University of Exeter
Recruiting --> Completed | Trial completion date: Jun 2016 --> Mar 2016 N=90 --> 0 | Trial completion date: Jan 2019 --> Dec 2017 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Jan 2018 --> Jun 2017
- | bortezomib / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder (clinicaltrials.gov) - Oct 16, 2018
P2, N=5, Completed, Sponsor: Tianjin Medical University General Hospital
N=90 --> 0 | Trial completion date: Jan 2019 --> Dec 2017 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Jan 2018 --> Jun 2017 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2017 | Trial primary completion date: Oct 2017 --> Dec 2016
- | Trial completion: SSENIOR: Pruritus and Pemphigoid in Nursing Home Patients (clinicaltrials.gov) - Oct 15, 2018
P=N/A, N=125, Completed, Sponsor: M.F. Jonkman
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2017 | Trial primary completion date: Oct 2017 --> Dec 2016 Active, not recruiting --> Completed
- | staphylococcal protein A (PRTX-100) / Protalex
Trial primary completion date: PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP (clinicaltrials.gov) - Oct 15, 2018
P1b, N=30, Recruiting, Sponsor: Protalex, Inc.
Active, not recruiting --> Completed Trial primary completion date: Sep 2018 --> Dec 2018
- | Trial completion, Trial completion date, Trial primary completion date: PBR28 PET and Inflammatory Arthritis (clinicaltrials.gov) - Oct 13, 2018
P=N/A, N=22, Completed, Sponsor: University of Oxford
Trial primary completion date: Sep 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2017 | Trial primary completion date: Nov 2017 --> Jul 2017
- | Trial completion date, Trial primary completion date: "MS-Fit": Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis (clinicaltrials.gov) - Oct 12, 2018
P=N/A, N=62, Recruiting, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2017 | Trial primary completion date: Nov 2017 --> Jul 2017 Trial completion date: Jul 2018 --> Mar 2019 | Trial primary completion date: Jul 2018 --> Dec 2018
- | Trial primary completion date: T1REDEEM: Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes (clinicaltrials.gov) - Oct 11, 2018
P=N/A, N=290, Active, not recruiting, Sponsor: University of California, San Francisco
Trial completion date: Jul 2018 --> Mar 2019 | Trial primary completion date: Jul 2018 --> Dec 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- | dimethyl fumarate / Generic mfg.
Trial completion, Trial completion date: DIMAT-MS: Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 11, 2018
P4, N=67, Completed, Sponsor: University Hospital Muenster
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> May 2018
- | Trial completion, Enrollment change: Changes in Arterial Stiffness and Endothelial Glycocalyx in Patients With Poorly Controlled Diabetes Mellitus Type 1 or Type 2 After Optimization of Antidiabetic Medication. (clinicaltrials.gov) - Oct 11, 2018
P=N/A, N=100, Completed, Sponsor: University of Athens
Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> May 2018 Recruiting --> Completed | N=60 --> 100
- | Trial completion, Trial completion date, Trial primary completion date: Brown Adipose Tissue in Type 1 Diabetes (clinicaltrials.gov) - Oct 11, 2018
P=N/A, N=11, Completed, Sponsor: Per-Ola Carlsson
Recruiting --> Completed | N=60 --> 100 Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Jun 2018 | Trial primary completion date: Sep 2018 --> Jan 2018
- | losartan potassium / Generic mfg.
Trial completion, Trial completion date: Efficacy and Safety of Losartan in Children With Ig A Nephropathy (clinicaltrials.gov) - Oct 11, 2018
P3, N=37, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Jun 2018 | Trial primary completion date: Sep 2018 --> Jan 2018 Active, not recruiting --> Completed | Trial completion date: Nov 2017 --> Apr 2017
- | JNJ-55920839 / J&J
Trial completion: A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 10, 2018
P1, N=76, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | Trial completion date: Nov 2017 --> Apr 2017 Active, not recruiting --> Completed
- | Trial completion: Multi-Colored Placido Disk Viability (clinicaltrials.gov) - Oct 5, 2018
P=N/A, N=16, Completed, Sponsor: University of Rochester
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date, Pneumococcal vaccines: Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar® (clinicaltrials.gov) - Oct 4, 2018
P4, N=505, Completed, Sponsor: Region Skane
Active, not recruiting --> Completed Enrolling by invitation --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Dec 2018 --> Jan 2018
- | Trial completion, Trial primary completion date: FMD-ABRA: Full Mouth Disinfection and Antibiotics for Periodontitis in High or Moderate Disease Activity Rheumatoid Arthritis (clinicaltrials.gov) - Oct 4, 2018
P=N/A, N=8, Completed, Sponsor: University Hospital Inselspital, Berne
Enrolling by invitation --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Dec 2018 --> Jan 2018 Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Aug 2017
- || AZD9567 / AstraZeneca
Enrollment change: A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567. (clinicaltrials.gov) - Oct 4, 2018
P1, N=72, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Aug 2017 N=48 --> 72
- | BMS-986142 / BMS, lulizumab pegol (BMS-931699) / BMS
Enrollment change: Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sj (clinicaltrials.gov) - Oct 4, 2018
P2, N=45, Terminated, Sponsor: Bristol-Myers Squibb
N=48 --> 72 N=80 --> 45
- | Trial completion: SCI-COG: Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI (clinicaltrials.gov) - Oct 3, 2018
P=N/A, N=117, Completed, Sponsor: University Hospital, Bordeaux
N=80 --> 45 Active, not recruiting --> Completed
- | Trial completion: Pilot Diet Study for Multiple Sclerosis (clinicaltrials.gov) - Oct 3, 2018
P=N/A, N=36, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion date, Trial initiation date, Trial primary completion date: Edu4U: The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Sep 28, 2018
P=N/A, N=178, Not yet recruiting, Sponsor: University of Louisville
Active, not recruiting --> Completed Trial completion date: May 2020 --> Dec 2020 | Initiation date: Aug 2018 --> Mar 2019 | Trial primary completion date: Nov 2018 --> May 2020
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Glucose variability: Glucose Variability in Patients With Type 1 Diabetes With a Sucrose-added Diet (clinicaltrials.gov) - Sep 28, 2018
P=N/A, N=10, Completed, Sponsor: Universidade Federal do Rio de Janeiro
Trial completion date: May 2020 --> Dec 2020 | Initiation date: Aug 2018 --> Mar 2019 | Trial primary completion date: Nov 2018 --> May 2020 Recruiting --> Completed | N=30 --> 10 | Trial completion date: Dec 2019 --> Jan 2018 | Trial primary completion date: Dec 2017 --> Jul 2017
- | Trial completion, Trial completion date: Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases. (clinicaltrials.gov) - Sep 26, 2018
P=N/A, N=24, Completed, Sponsor: Brown, Theodore R., M.D., MPH
Recruiting --> Completed | N=30 --> 10 | Trial completion date: Dec 2019 --> Jan 2018 | Trial primary completion date: Dec 2017 --> Jul 2017 Recruiting --> Completed | Trial completion date: Dec 2018 --> Aug 2018
- | glatiramer acetate / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment change, Trial withdrawal: High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 26, 2018
P2, N=0, Withdrawn, Sponsor: Johns Hopkins University
Recruiting --> Completed | Trial completion date: Dec 2018 --> Aug 2018 N=12 --> 0 | Suspended --> Withdrawn
- | Clinical data, Trial completion, Trial completion date, Trial primary completion date, Adverse events: Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions (clinicaltrials.gov) - Sep 26, 2018
P=N/A, N=3000, Completed, Sponsor: Elliot Lander
N=12 --> 0 | Suspended --> Withdrawn Recruiting --> Completed | Trial completion date: Mar 2018 --> Jan 2017 | Trial primary completion date: Mar 2018 --> Dec 2016
- | Enrollment change, Trial withdrawal: Tissue Sodium in Autoimmune Disease (clinicaltrials.gov) - Sep 26, 2018
P=N/A, N=0, Withdrawn, Sponsor: Vanderbilt University
Recruiting --> Completed | Trial completion date: Mar 2018 --> Jan 2017 | Trial primary completion date: Mar 2018 --> Dec 2016 N=21 --> 0 | Not yet recruiting --> Withdrawn
- | Trial completion date: Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes (clinicaltrials.gov) - Sep 25, 2018
P=N/A, N=124, Active, not recruiting, Sponsor: Medtronic Diabetes
N=21 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Jun 2018 --> Oct 2018
- | Enrollment closed, Video: Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis (clinicaltrials.gov) - Sep 24, 2018
P=N/A, N=31, Active, not recruiting, Sponsor: Ohio State University
Trial completion date: Jun 2018 --> Oct 2018 Recruiting --> Active, not recruiting
- | Trial termination, Biopsy: Collection of Blood, Bone Marrow, Leukapheresis, and Tissue Biopsy Samples From Patients and Their Family Members for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases Laboratory Research Studies (clinicaltrials.gov) - Sep 20, 2018
P=N/A, N=96, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Completed --> Terminated
- ||||| Erelzi (etanercept biosimilar) / Novartis
Trial initiation date: EQUIRA: Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 19, 2018
P3, N=376, Completed, Sponsor: Sandoz
Completed --> Terminated Initiation date: Nov 2015 --> Feb 2015
- | Trial termination: HORTIM: Interest of Medical Imaging in the Diagnostic Strategy Vis a Vis a Suspected Horton Disease (clinicaltrials.gov) - Sep 18, 2018
P=N/A, N=45, Terminated, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Initiation date: Nov 2015 --> Feb 2015 Recruiting --> Terminated
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Scorpio Non Restricted Geometry (NRG) Study in Japan (clinicaltrials.gov) - Sep 17, 2018
P=N/A, N=150, Completed, Sponsor: Stryker Japan K.K.
Recruiting --> Terminated Recruiting --> Completed | N=300 --> 150 | Trial completion date: Sep 2019 --> Mar 2018 | Trial primary completion date: Sep 2019 --> Mar 2018
- | Biomarker, Trial completion, Trial completion date, Trial primary completion date, Immunomodulating: The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients (clinicaltrials.gov) - Sep 17, 2018
P2, N=41, Completed, Sponsor: Tabriz University of Medical Sciences
Recruiting --> Completed | N=300 --> 150 | Trial completion date: Sep 2019 --> Mar 2018 | Trial primary completion date: Sep 2019 --> Mar 2018 Recruiting --> Completed | Trial completion date: Sep 2018 --> Nov 2017 | Trial primary completion date: Aug 2018 --> Aug 2017
- || namilumab (IZN-101) / Amgen, Izana Biosci
Trial primary completion date, Combination therapy: NEXUS: Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Sep 14, 2018
P2, N=108, Completed, Sponsor: Takeda
Recruiting --> Completed | Trial completion date: Sep 2018 --> Nov 2017 | Trial primary completion date: Aug 2018 --> Aug 2017 Trial primary completion date: Nov 2016 --> May 2016
- | Trial completion: MSCopilot: Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients (clinicaltrials.gov) - Sep 14, 2018
P=N/A, N=222, Completed, Sponsor: Ad scientiam
Trial primary completion date: Nov 2016 --> May 2016 Active, not recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date: GASTRO-SGS: Evaluation of the Prevalence of Functional Digestive Disorders During Primary Sjögren Gougerot Syndrome (clinicaltrials.gov) - Sep 13, 2018
P=N/A, N=151, Completed, Sponsor: University Hospital, Limoges
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Jan 2019 --> Jun 2018 | Trial primary completion date: Jan 2019 --> Jun 2018
- | Tysabri (natalizumab) / Biogen, Royalty
Trial completion, Trial completion date, Trial primary completion date, HEOR: PROTYS: Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab (clinicaltrials.gov) - Sep 13, 2018
P=N/A, N=48, Completed, Sponsor: Biogen
Recruiting --> Completed | Trial completion date: Jan 2019 --> Jun 2018 | Trial primary completion date: Jan 2019 --> Jun 2018 Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Jan 2018 | Trial primary completion date: Aug 2018 --> Jan 2018
- | mycophenolate mofetil / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis (clinicaltrials.gov) - Sep 12, 2018
P=N/A, N=84, Completed, Sponsor: Ramathibodi Hospital
Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Jan 2018 | Trial primary completion date: Aug 2018 --> Jan 2018 Recruiting --> Completed | Trial completion date: Dec 2016 --> Mar 2017 | Trial primary completion date: Dec 2016 --> Mar 2017
- | Trial completion, Enrollment change: BUHD-SPINA: Urinary Markers of Detrusor Overactivity in Spina Bifida Patients (clinicaltrials.gov) - Sep 11, 2018
P=N/A, N=134, Completed, Sponsor: Rennes University Hospital
Recruiting --> Completed | Trial completion date: Dec 2016 --> Mar 2017 | Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Completed | N=198 --> 134
- | Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases (clinicaltrials.gov) - Sep 10, 2018
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Recruiting --> Completed | N=198 --> 134 N=15 --> 0 | Trial completion date: Jun 2018 --> Sep 2018 | Suspended --> Withdrawn | Trial primary completion date: Jun 2018 --> Sep 2018
- | allopurinol / Generic mfg.
Trial completion: MIKAL: Microalbuminuria and Allopurinol in Type 1 Diabetes (clinicaltrials.gov) - Sep 10, 2018
P4, N=30, Completed, Sponsor: Peter Rossing
N=15 --> 0 | Trial completion date: Jun 2018 --> Sep 2018 | Suspended --> Withdrawn | Trial primary completion date: Jun 2018 --> Sep 2018 Active, not recruiting --> Completed
- | Trial completion, Phase classification: Efficacy of MBI for Depressive Symptoms in Patients With MS (clinicaltrials.gov) - Sep 7, 2018
P=N/A, N=88, Completed, Sponsor: University of Turin, Italy
Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: P4 --> PN/A
- || prezalumab (AMG 557) / Amgen, AstraZeneca
Trial completion: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Sep 6, 2018
P2a, N=32, Completed, Sponsor: MedImmune LLC
Recruiting --> Completed | Phase classification: P4 --> PN/A Active, not recruiting --> Completed
- | Trial completion: Physical Activity Monitoring Paediatric Type 1 Diabetes (clinicaltrials.gov) - Sep 6, 2018
P=N/A, N=13, Completed, Sponsor: Sheffield Hallam University
Active, not recruiting --> Completed Not yet recruiting --> Completed
- ||| Trial completion: VALUE: Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 6, 2018
P=N/A, N=80, Completed, Sponsor: Lupus Research Alliance
Not yet recruiting --> Completed Active, not recruiting --> Completed